Griderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Griderm

Property Description
Active ingredient Griseofulvin (C17H17ClO6)
Form Oral Tablet (Microsize/Ultramicrosize) or Suspension
Pharmacological class Systemic Antifungal Agent (Antimycotic)
General purpose Management of dermatophytosis (ringworm)
Origin Synthetic (derived from Penicillium species)

What Type of Medicine is Griderm?

Griderm is a prescription-only medication containing the active ingredient Griseofulvin, classified as a systemic antifungal agent. It is primarily developed for the management of fungal infections that are persistent or deep-seated and not effectively reached by topical creams. Griseofulvin is clinically recognized for its use against various forms of dermatophytosis, or ringworm, including those affecting the scalp and nails. As an orally administered drug, Griseofulvin provides systemic therapy meaning the medicine is absorbed internally and distributed throughout the body via the bloodstream. This approach is fundamental for treating fungal infections that have penetrated tissues beyond the skin surface.


Composition, Forms, and General Principle

The active ingredient, Griseofulvin, is a synthetic compound manufactured as a single-product formulation. It is typically available as an oral tablet or oral suspension. To ensure effective therapeutic action, the substance is manufactured using specialized particle sizes: microsize or ultramicrosize. Pharmacological studies confirm that this specialized particle structure is critical for enhancing the drug's poor oral absorption and bioavailability. Griseofulvin functions as a fungistatic agent, meaning its primary action is to halt the growth and multiplication of the fungal organism. Once absorbed, the compound binds to keratin precursors, creating an internal protective barrier against the pathogen in new, forming tissue, which facilitates the natural resolution of the infection over time.

Regulatory References

  1. Griseofulvin - MedlinePlus Drug Information

What side effects are possible with Griderm?

Possible Side Effects and Safety Information

The official safety information for Griderm details a range of possible adverse reactions, from common, expected events to rare, clinically significant risks that have led to specific regulatory warnings.


Serious and Clinically Significant Risks

Regulators have highlighted the risk of Severe Cutaneous Adverse Reactions (SCARs), which are potentially life-threatening skin disorders. These serious adverse events include:

  • Stevens-Johnson syndrome (SJS)
  • Toxic Epidermal Necrolysis (TEN)
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
  • Acute Generalized Exanthematous Pustulosis (AGEP)

Other serious risks include liver damage (hepatotoxicity) and the onset of lupus-like symptoms.

Safety-Related Restrictions and Contraindications

Griderm must not be used in the following circumstances, which are considered definitive limitations based on official regulatory documents:

  • Patients with porphyria (a group of rare blood disorders).
  • Patients with severe liver disease or liver failure.
  • During pregnancy, as it is classified as contraindicated due to the risk of fetal harm.

Common and Less Common Adverse Reactions

The most commonly reported adverse reactions often involve the gastrointestinal system and nervous system. These events may include:

  • Headache, dizziness, or confusion.
  • Nausea, vomiting, diarrhea, or upset stomach.
  • Insomnia.
  • Skin rashes and hives (urticaria).

Less common events include photosensitivity, which is an increased sensitivity of the skin to sunlight or artificial light sources.

Official Regulatory Classifications

Category Description
System-Organ Class Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders, Nervous System Disorders
Serious Reaction Severe Cutaneous Adverse Reactions (SCARs)
Frequency Classification Adverse events are documented based on clinical trials and post-marketing surveillance, classified by frequency (e.g., common, rare, frequency not known).

Note: If a severe rash or symptoms of an allergic or liver reaction develop, immediate discontinuation is a necessary step as directed by regulatory guidance. The official safety structure is designed to first communicate these most critical risks.

Overdose and Emergency Response

The official regulatory documents state that the specific symptoms following a massive acute Griderm (Griseofulvin) overdose are not well characterized. However, documented manifestations based on high-dose exposure may include common gastrointestinal effects such as nausea, vomiting, and diarrhea, along with neurological signs like headache, confusion, and paresthesia.

In any case of suspected overdose or significant accidental ingestion, immediate medical attention must be sought. It is required to call a national Poison Control helpline for guidance. Urgent emergency services must be contacted immediately if the individual experiences severe symptoms such as collapse, seizure, difficulty breathing, or inability to be awakened.

Management procedures are primarily symptomatic and supportive. There is no specific antidote known. Depending on the amount and time of ingestion, medical professionals may consider procedures like gastric lavage or the administration of activated charcoal to limit drug absorption. Immediate medical help is also required if severe, high-dose-related systemic toxicities emerge, including signs of hepatotoxicity (e.g., jaundice, pale stools) or severe blistering skin reactions, as these are considered life-threatening complications requiring prompt medical intervention.

Therapeutic Uses of Griderm

Quick Facts

  • Condition: Fungal infections (Dermatophytosis)
  • Main Areas: Skin, hair, scalp, fingernails, and toenails
  • Action: Helps address the underlying fungal organism

Griderm is an approved oral medication utilized to manage certain types of fungal infections, which are also commonly referred to as ringworm. It is typically reserved for infections of the skin, hair, and nails that have not responded adequately to topical treatments, such as creams and lotions.

The medication is indicated for use in addressing various forms of ringworm, including tinea capitis (ringworm of the scalp), tinea corporis (ringworm of the body), tinea cruris (ringworm of the groin, or jock itch), and tinea pedis (athlete’s foot). It may also be used to treat infections affecting the fingernails and toenails (tinea unguium/onychomycosis).

It is important to understand that the full therapeutic effect may require several weeks or months of consistent use, especially for nail infections, as the medication must become incorporated into new growth to help resolve the condition. Griderm is an option to consider for treating these specific fungal infections, helping to control the spread of the infection and supporting the return to overall well-being.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Griderm (Griseofulvin) is subject to specific regulatory eligibility criteria based on patient population and pre-existing conditions, defining who can and who must not use the medicine.

Use is absolutely contraindicated in patients with Porphyria, Hepatocellular Failure (severe liver failure), and individuals with a known Hypersensitivity to Griseofulvin or its components. It is also contraindicated during pregnancy due to the risk of fetal harm. Use in breastfeeding women is generally advised against by regulatory authorities.

Reproductive restrictions are strict for both sexes: women of childbearing potential must use effective contraception during therapy and for at least four weeks after the last dose. Separately, sexually active male patients are advised by regulators to use contraception for six months following the completion of treatment.

For age-related eligibility, the safety and efficacy are not established in infants and children two years of age and younger. While the medicine is not adjusted for renal impairment, patients with pre-existing mild or moderate hepatic impairment are only eligible under the condition of regular liver function monitoring. The use may also be restricted or require caution in patients with Systemic Lupus Erythematosus (SLE).

What should I know about interactions with other medicines?

Griderm's interaction profile is primarily structured by its function as a hepatic microsomal enzyme inducer. This pharmacokinetic effect is officially documented to decrease the activity and therapeutic efficacy of several concomitant medications, including oral contraceptives (estrogen-containing) and warfarin-type anticoagulants. The resulting interaction with oral contraceptives mandates that patients use effective barrier contraception during therapy and for four weeks following treatment cessation for females, and for six months for males.

A significant pharmacodynamic restriction involves alcohol (ethanol), co-administration of which is officially linked to the risk of a Disulfiram-type reaction (e.g., flushing, vomiting, and tachycardia). Other documented interactions include Barbiturates (such as Phenobarbital) which decrease the plasma concentration of Griderm. Conversely, the drug’s own absorption is significantly enhanced when administered with a high-fat meal or milk, a critical factor for adequate systemic exposure. Finally, the medicine is formally contraindicated in populations with Porphyria or severe liver disease.

Mechanism of Action

Griderm functions at the molecular level as a specific, non-competitive inhibitor of the enzyme Farnesyl Pyrophosphate Synthase ( FPPS). This enzyme is a critical catalyst within the mevalonate pathway. Griderm's binding within the isoprenoid domain prevents the synthesis of key downstream lipid precursors, including farnesyl pyrophosphate ( FPP) and geranylgeranyl pyrophosphate ( GGPP).

The subsequent reduction in FPP and GGPP availability directly disrupts the post-translational modification of signaling proteins, primarily the process known as prenylation. This cascade specifically impacts the activation of small GTPases ( Rho, Rac, Cdc42), which require prenylation for membrane anchoring and functional activity. By effectively inactivating these essential signaling proteins, Griderm modulates intracellular processes.

This GTPase inactivation leads to a system-level physiological consequence by modifying the integrity of the actin cytoskeleton. The resulting functional change reduces the cellular migration capacity and alters the overall trafficking and functional status of various immune cells within affected tissues.

Dosage and Administration Information

The administration of Griderm (Griseofulvin) is defined by official instructions regarding route, dosage, and timing to ensure proper systemic delivery. The medication is approved exclusively for oral administration.

Dosing regimens vary based on the particle size of the formulation—Microsize or Ultramicrosize—and the specific location of the fungal infection. The total daily dose, which ranges from 375 mg to 1000 mg for adults depending on the formulation and severity, may be taken either as a single dose or in divided doses.

A critical administration requirement is that Griderm must be taken with or immediately after a meal, particularly a fatty meal, as this condition significantly enhances the drug's absorption and bioavailability. The oral suspension formulation requires shaking well before measuring.

Age-Group Administration Rules

For pediatric patients older than two years, the official dosing is determined by weight (e.g., 10–20 mg/kg/day for the Microsize form). Use is generally not established for children under two years of age.

Course Duration

Treatment constitutes a continuous daily course, with the duration directly correlated to the body part being treated: approximately 2 to 4 weeks for skin infections, but extending to 6 to 12 months or longer for nail infections. If a dose is missed, official guidance advises taking it as soon as remembered, unless it is close to the next scheduled time, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Griderm

Evidence Supporting Use in Ringworm of the Scalp (Tinea Capitis)

Research examining Griderm for tinea capitis, which is a condition involving periods of heightened symptom activity, has utilized Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies primarily focused on pediatric populations, since this condition is most commonly observed in children. The research efforts typically monitored outcomes over defined, short-term intervals, including measures related to physical discomfort. Researchers aimed to measure the mycological conversion rate and the corresponding change in physical signs.

Studies described patterns related to the various rates of mycological conversion and clinical sign changes observed in the populations following the study period. However, certain aspects remain uncertain about the full evidence landscape. Long-term outcomes regarding the stability of the mycological conversion and the rate of infection recurrence are not fully established, as follow-up durations were limited in many studies.

Evidence Supporting Use in Fungal Nail Infections (Onychomycosis)

Griderm was evaluated in studies for fungal nail infections, which are conditions marked by functional limitations and require extended observation periods. Because the condition involves slow-growing tissues, the research utilized long-term Randomized Controlled Trials and Comparative Trials. The outcomes monitored involved tracking the time required for new, unaffected nail growth over many months. Study populations were typically adult patients.

Research highlights changes measured during the study period, indicating that prolonged treatment durations (often many months) was observed in some studies to allow for the assessment of full nail resolution. Studies reported that the long duration of treatment was linked to difficulties in collecting consistent data throughout the study period. There is limited information for long-term outcomes specifically addressing older adults who may have coexisting health conditions.

Gaps in Research and Areas of Uncertainty

While studies help show what has been observed so far, a significant gap exists due to variability in outcome definitions across different trials, which can make direct comparisons difficult. Comparative evidence is lacking in some areas where Griderm could be compared directly against contemporary treatments in large, head-to-head trials. Overall, research provides insight into short-term changes, but there is limited information for long-term outcomes and the research does not determine whether an individual will respond similarly to the group patterns observed.

Frequently Asked Questions (FAQ)

Common questions about Griderm (FAQ)

Q: How is Griderm different from a topical antifungal cream?

Griderm is a systemic antifungal medication, meaning it is taken by mouth and absorbed into the bloodstream to treat infections from the inside out. Official product information states it is used for infections that are generally not amenable to treatment with topical creams alone, such as those that are deep-seated in the hair or nails.

Q: How does Griderm actually stop the fungus from growing?

Griderm is classified as a fungistatic agent, which means its main action is to halt the fungal organism from growing and multiplying. Regulatory documents indicate that the medicine works by binding to the keratin in newly forming skin, hair, and nails, making this new tissue resistant to subsequent fungal invasion.

Q: Why does Griderm treatment often last for so many weeks or months?

The treatment duration is directly related to how long it takes for the body to replace all the infected tissue with new, uninfected tissue. This natural replacement process is very slow, especially for toenails, which is why regulatory information shows that treatment can often require six months to a year or longer.

Q: What are the typical recovery times for nail infections treated with Griderm?

Because nails grow slowly, the full treatment duration required to address a nail infection can be long. According to official regulatory information, continuous treatment for nail infections is generally required for 6 months up to 12 months or longer to allow for the growth of new, healthy nail tissue.

Q: How quickly can I expect to see an improvement in a skin infection after starting Griderm?

While symptomatic improvement for skin infections may begin within a few days of starting the medication, it is important to continue Griderm for the full prescribed duration. For skin infections, this continuous course is often a minimum of 2 to 4 weeks until the infected skin is fully replaced.

Q: What is the connection between Griderm and Keratin in the body?

The official product information explains that Griderm is deposited into the keratin precursor cells (the cells that form hair, skin, and nails). Once there, it binds to the new keratin, which protects the emerging tissue and makes it resistant to subsequent fungal invasion.

Q: Why is taking Griderm with a high-fat meal or milk recommended?

Official regulatory documents emphasize that Griderm must be taken with or immediately after a meal, especially one containing fat. This is because the fatty content significantly enhances the absorption and bioavailability of the drug, which is critical for achieving adequate systemic exposure.

Q: Can taking Griderm on an empty stomach reduce its effectiveness?

Yes, taking Griderm without food or a high-fat meal can lead to inadequate absorption of the medicine into the bloodstream. This can reduce the drug's absorption and therapeutic effect.

Q: What happens if I stop taking Griderm before the full course is finished?

Official product warnings advise against stopping the treatment course too early. If Griderm is stopped prematurely, the infection may not be fully eliminated, and there is a risk that the fungal infection could come back (recur).

Q: Is it common to feel unusually tired or fatigued while taking Griderm?

Official safety data lists unusual tiredness or weakness as a potential adverse reaction. However, severe fatigue is also listed as a symptom that may indicate a serious liver problem. Discuss any symptoms, especially severe ones, with a healthcare professional.

Q: Is it common to feel nauseous or dizzy when first starting Griderm?

According to official regulatory sources, adverse reactions such as nausea, vomiting, headache, and dizziness are among the common effects reported. These symptoms have often been observed to lessen as therapy continues.

Q: Is a severe headache a normal side effect of Griderm?

Headache is listed in official safety information as a common side effect of Griderm. Some reports indicate that headaches have been severe but typically resolve as therapy continues. It is important to discuss any persistent or severe symptoms with a healthcare professional.

Q: Are there any long-term side effects associated with Griderm use?

Serious side effects have been reported after extended therapy, including a tingling or 'pins-and-needles' feeling (paresthesia) in the hands and feet. Also, regulatory information notes that long-term animal studies reported tumor development, but the clinical significance of these findings for humans is not fully established.

Q: Can Griderm interact with blood thinners like Warfarin?

Yes, official drug interaction warnings state that Griderm can decrease the effect and therapeutic efficacy of coumarin-type anticoagulants, such as Warfarin. Official warnings state that a dosage adjustment of the blood thinner may be necessary, and monitoring may be required.

Q: Are there any herbal supplements that should be avoided while on Griderm?

Official regulatory documents contain warnings about interactions with certain prescription and over-the-counter drugs, but they do not list specific herbal supplements. It is recommended to review all concomitant medicines and supplements with a healthcare provider.

Q: Why is Griderm generally contraindicated for pregnant or breastfeeding women?

Griderm is formally contraindicated during pregnancy due to the confirmed risk of fetal harm. For breastfeeding, official safety guidance states that the drug's safety has not been established, and some authorities advise against its use or recommend stopping breastfeeding during therapy.

Q: Is there a known cross-sensitivity or allergy risk with penicillin?

Official regulatory information indicates that a hypersensitivity cross-reaction between penicillins and Griderm is possible. However, there are reports that some patients with known penicillin sensitivity have been treated successfully with Griderm without adverse reactions.

Q: Can Griderm cause issues with driving or operating heavy machinery?

Official safety data warns that Griderm may cause some people to become dizzy, drowsy, or confused. Official warnings suggest knowing how the medicine affects you before engaging in activities that require full mental alertness, such as driving or operating heavy machinery.

Q: Does Griderm treat yeast infections like Candida (Oral Thrush)?

No, official indications state that Griderm is not effective against infections caused by Candida (monilia) or other common yeasts like Malassezia furfur. Its use is specifically limited to infections caused by susceptible species of dermatophytes (ringworm).

Q: Can taking Griderm cause trouble sleeping or insomnia?

Yes, regulatory safety documents list insomnia (trouble sleeping) as an adverse reaction that has been reported by some patients taking Griderm.

Q: Why is proper hygiene important while being treated with Griderm?

Official patient counseling information states that general hygienic measures should be used alongside Griderm therapy. This is meant to help control the fungal infection and actively prevent the patient from becoming reinfected.

Q: Is Griderm an antibiotic or a steroid?

Official product descriptions classify Griderm (Griseofulvin) as a fungistatic antibiotic or antifungal agent. It is used to inhibit the growth of fungi, and it is not a steroid.

Q: What should I know about using Griderm for Tinea Capitis (scalp ringworm)?

Griderm is often listed in regulatory documents as a drug of choice for the treatment of Tinea Capitis (ringworm of the scalp). However, official information stresses that a prolonged course is often necessary, and non-compliance with the full course may affect the clinical outcome.

Q: Why is Griderm sometimes used only when other topical treatments have failed?

According to official indications, the use of Griderm is generally reserved for fungal infections that are either not amenable to, or will not respond to, topical antifungal agents alone. This typically applies to more extensive or deep-seated infections.

How should Griderm be stored and disposed of?

How to Store and Dispose of Griderm

Official regulatory documents define strict requirements for storing and disposing of Griderm (Griseofulvin) to maintain its quality and ensure safety.

Storage and Handling Requirements

  • Temperature and Environment: Store the medication at or below 25 C or at room temperature. The product must be protected from light, moisture, and excess heat. Do not store in a bathroom, and specifically, the liquid formulation must not be frozen.
  • Container Integrity: Keep the medication in its original container, which must be kept tightly closed. The oral suspension should be shaken well before each use.
  • Child Safety: It is mandatory to keep Griderm out of the reach and sight of children, storing it in a safe, secured location. Safety caps must always be locked.

Disposal Instructions

Unused or expired Griderm must be disposed of according to the official guidelines provided by the local drug authority or a pharmacist. Do not flush the medication down a toilet or pour it down a drain unless specifically instructed to do so by a regulated program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Griderm found in:

A-Z Index: